Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Standard

Genomic heterogeneity in bladder cancer : challenges and possible solutions to improve outcomes. / Meeks, Joshua J.; Al-Ahmadie, Hikmat; Faltas, Bishoy M.; Taylor, John A.; Flaig, Thomas W.; DeGraff, David J.; Christensen, Emil; Woolbright, Benjamin L.; McConkey, David J.; Dyrskjøt, Lars.

I: Nature Reviews Urology, Bind 17, Nr. 5, 05.2020, s. 259-270.

Publikation: Bidrag til tidsskrift/Konferencebidrag i tidsskrift /Bidrag til avisReviewForskningpeer review

Harvard

Meeks, JJ, Al-Ahmadie, H, Faltas, BM, Taylor, JA, Flaig, TW, DeGraff, DJ, Christensen, E, Woolbright, BL, McConkey, DJ & Dyrskjøt, L 2020, 'Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes', Nature Reviews Urology, bind 17, nr. 5, s. 259-270. https://doi.org/10.1038/s41585-020-0304-1

APA

Meeks, J. J., Al-Ahmadie, H., Faltas, B. M., Taylor, J. A., Flaig, T. W., DeGraff, D. J., Christensen, E., Woolbright, B. L., McConkey, D. J., & Dyrskjøt, L. (2020). Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nature Reviews Urology, 17(5), 259-270. https://doi.org/10.1038/s41585-020-0304-1

CBE

Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA, Flaig TW, DeGraff DJ, Christensen E, Woolbright BL, McConkey DJ, Dyrskjøt L. 2020. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nature Reviews Urology. 17(5):259-270. https://doi.org/10.1038/s41585-020-0304-1

MLA

Vancouver

Meeks JJ, Al-Ahmadie H, Faltas BM, Taylor JA, Flaig TW, DeGraff DJ o.a. Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes. Nature Reviews Urology. 2020 maj;17(5):259-270. https://doi.org/10.1038/s41585-020-0304-1

Author

Meeks, Joshua J. ; Al-Ahmadie, Hikmat ; Faltas, Bishoy M. ; Taylor, John A. ; Flaig, Thomas W. ; DeGraff, David J. ; Christensen, Emil ; Woolbright, Benjamin L. ; McConkey, David J. ; Dyrskjøt, Lars. / Genomic heterogeneity in bladder cancer : challenges and possible solutions to improve outcomes. I: Nature Reviews Urology. 2020 ; Bind 17, Nr. 5. s. 259-270.

Bibtex

@article{1fbfc341a3c94e4b8e9b6d99c81e098e,
title = "Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes",
abstract = "Histological and molecular analyses of urothelial carcinoma often reveal intratumoural and intertumoural heterogeneity at the genomic, transcriptional and cellular levels. Despite the clonal initiation of the tumour, progression and metastasis often arise from subclones that can develop naturally or during therapy, resulting in molecular alterations with a heterogeneous distribution. Variant histologies in tumour tissues that have developed distinct morphological characteristics divergent from urothelial carcinoma are extreme examples of tumour heterogeneity. Ultimately, heterogeneity contributes to drug resistance and relapse after therapy, resulting in poor survival outcomes. Mutation profile differences between patients with muscle-invasive and metastatic urothelial cancer (interpatient heterogeneity) probably contribute to variability in response to chemotherapy and immunotherapy as first-line treatments. Heterogeneity can occur on multiple levels and averaging or normalizing these alterations is crucial for clinical trial and drug design to enable appropriate therapeutic targeting. Identification of the extent of heterogeneity might shape the choice of monotherapy or additional combination treatments to target different drivers and genetic events. Identification of the lethal tumour cell clones is required to improve survival of patients with urothelial carcinoma.",
author = "Meeks, {Joshua J.} and Hikmat Al-Ahmadie and Faltas, {Bishoy M.} and Taylor, {John A.} and Flaig, {Thomas W.} and DeGraff, {David J.} and Emil Christensen and Woolbright, {Benjamin L.} and McConkey, {David J.} and Lars Dyrskj{\o}t",
year = "2020",
month = may,
doi = "10.1038/s41585-020-0304-1",
language = "English",
volume = "17",
pages = "259--270",
journal = "Nature Reviews. Urology",
issn = "1759-4812",
publisher = "Nature Publishing Group",
number = "5",

}

RIS

TY - JOUR

T1 - Genomic heterogeneity in bladder cancer

T2 - challenges and possible solutions to improve outcomes

AU - Meeks, Joshua J.

AU - Al-Ahmadie, Hikmat

AU - Faltas, Bishoy M.

AU - Taylor, John A.

AU - Flaig, Thomas W.

AU - DeGraff, David J.

AU - Christensen, Emil

AU - Woolbright, Benjamin L.

AU - McConkey, David J.

AU - Dyrskjøt, Lars

PY - 2020/5

Y1 - 2020/5

N2 - Histological and molecular analyses of urothelial carcinoma often reveal intratumoural and intertumoural heterogeneity at the genomic, transcriptional and cellular levels. Despite the clonal initiation of the tumour, progression and metastasis often arise from subclones that can develop naturally or during therapy, resulting in molecular alterations with a heterogeneous distribution. Variant histologies in tumour tissues that have developed distinct morphological characteristics divergent from urothelial carcinoma are extreme examples of tumour heterogeneity. Ultimately, heterogeneity contributes to drug resistance and relapse after therapy, resulting in poor survival outcomes. Mutation profile differences between patients with muscle-invasive and metastatic urothelial cancer (interpatient heterogeneity) probably contribute to variability in response to chemotherapy and immunotherapy as first-line treatments. Heterogeneity can occur on multiple levels and averaging or normalizing these alterations is crucial for clinical trial and drug design to enable appropriate therapeutic targeting. Identification of the extent of heterogeneity might shape the choice of monotherapy or additional combination treatments to target different drivers and genetic events. Identification of the lethal tumour cell clones is required to improve survival of patients with urothelial carcinoma.

AB - Histological and molecular analyses of urothelial carcinoma often reveal intratumoural and intertumoural heterogeneity at the genomic, transcriptional and cellular levels. Despite the clonal initiation of the tumour, progression and metastasis often arise from subclones that can develop naturally or during therapy, resulting in molecular alterations with a heterogeneous distribution. Variant histologies in tumour tissues that have developed distinct morphological characteristics divergent from urothelial carcinoma are extreme examples of tumour heterogeneity. Ultimately, heterogeneity contributes to drug resistance and relapse after therapy, resulting in poor survival outcomes. Mutation profile differences between patients with muscle-invasive and metastatic urothelial cancer (interpatient heterogeneity) probably contribute to variability in response to chemotherapy and immunotherapy as first-line treatments. Heterogeneity can occur on multiple levels and averaging or normalizing these alterations is crucial for clinical trial and drug design to enable appropriate therapeutic targeting. Identification of the extent of heterogeneity might shape the choice of monotherapy or additional combination treatments to target different drivers and genetic events. Identification of the lethal tumour cell clones is required to improve survival of patients with urothelial carcinoma.

UR - http://www.scopus.com/inward/record.url?scp=85083251940&partnerID=8YFLogxK

U2 - 10.1038/s41585-020-0304-1

DO - 10.1038/s41585-020-0304-1

M3 - Review

C2 - 32235944

AN - SCOPUS:85083251940

VL - 17

SP - 259

EP - 270

JO - Nature Reviews. Urology

JF - Nature Reviews. Urology

SN - 1759-4812

IS - 5

ER -